GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (OTCPK:COTXF) » Definitions » EV-to-EBITDA

Cyprotex (Cyprotex) EV-to-EBITDA : -17.69 (As of May. 08, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cyprotex EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cyprotex's enterprise value is $34.60 Mil. Cyprotex's EBITDA for the trailing twelve months (TTM) ended in Jun. 2016 was $-1.96 Mil. Therefore, Cyprotex's EV-to-EBITDA for today is -17.69.

The historical rank and industry rank for Cyprotex's EV-to-EBITDA or its related term are showing as below:

COTXF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 10.2
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-08), Cyprotex's stock price is $1.54. Cyprotex's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $-0.231. Therefore, Cyprotex's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Cyprotex EV-to-EBITDA Historical Data

The historical data trend for Cyprotex's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex EV-to-EBITDA Chart

Cyprotex Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.56 9.64 -106.64 -6.73 -8.25

Cyprotex Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -6.73 - -8.25 -

Competitive Comparison of Cyprotex's EV-to-EBITDA

For the Biotechnology subindustry, Cyprotex's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyprotex's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyprotex's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cyprotex's EV-to-EBITDA falls into.



Cyprotex EV-to-EBITDA Calculation

Cyprotex's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=34.600/-1.956
=-17.69

Cyprotex's current Enterprise Value is $34.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyprotex's EBITDA for the trailing twelve months (TTM) ended in Jun. 2016 was $-1.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyprotex  (OTCPK:COTXF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cyprotex's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.54/-0.231
=At Loss

Cyprotex's share price for today is $1.54.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyprotex's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $-0.231.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Cyprotex EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cyprotex's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyprotex (Cyprotex) Business Description

Traded in Other Exchanges
N/A
Address
Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (Cyprotex) Headlines

No Headlines